PriceTargets.com logo

Vincerx Pharma - VINC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 852.38%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.21 As of 12/20/2024 06:31 PM ET
▲ +0.0032 (1.55%)

This chart shows the closing price for VINC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vincerx Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VINC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VINC

Analyst Price Target is $2.00
▲ +852.38% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vincerx Pharma in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 852.38% upside from the last price of $0.21.

This chart shows the closing price for VINC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Vincerx Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2024Leerink PartnersLower TargetOutperform ➝ Outperform$4.00 ➝ $2.00
4/9/2024Cantor FitzgeraldReiterated RatingOverweight
4/1/2024Cantor FitzgeraldReiterated RatingOverweight
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$5.00
11/16/2022Chardan CapitalLower TargetBuy$4.00 ➝ $3.00
9/21/2022Cantor FitzgeraldReiterated RatingOverweight
8/12/2022Leerink PartnersLower TargetOutperform$6.00 ➝ $5.00
6/8/2022Cantor FitzgeraldLower Target$22.00 ➝ $8.00
6/7/2022B. RileyLower TargetBuy$12.00 ➝ $6.00
6/7/2022Chardan CapitalLower TargetBuy$11.00 ➝ $4.00
6/7/2022Leerink PartnersLower TargetOutperform$19.00 ➝ $6.00
4/12/2022B. RileyLower Target$26.00 ➝ $12.00
3/30/2022Leerink PartnersLower TargetOutperform$24.00 ➝ $20.00
3/30/2022Chardan CapitalLower Target$30.00 ➝ $14.00
3/29/2022Chardan CapitalReiterated RatingBuy
3/29/2022HC WainwrightBoost TargetBuy$25.00 ➝ $28.00
3/22/2022Chardan CapitalReiterated RatingBuy
1/14/2022HC WainwrightInitiated CoverageBuy$25.00
12/23/2021Cantor FitzgeraldInitiated CoverageOverweight$25.00
12/17/2021Chardan CapitalReiterated RatingBuy$30.00
12/14/2021Leerink PartnersReiterated RatingBuy
11/1/2021Leerink PartnersInitiated CoverageOutperform$24.00
9/13/2021LaidlawInitiated CoverageBuy$30.00
8/25/2021B. RileyInitiated CoverageBuy$26.00
8/13/2021Chardan CapitalLower TargetBuy$33.00 ➝ $30.00
1/6/2021Chardan CapitalInitiated CoverageBuy$33.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

-0.66 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Vincerx Pharma logo
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
Read More

Today's Range

Now: $0.21
Low: $0.18
High: $0.22

50 Day Range

MA: $0.30
Low: $0.19
High: $0.41

52 Week Range

Now: $0.21
Low: $0.18
High: $9.37

Volume

676,844 shs

Average Volume

673,799 shs

Market Capitalization

$7.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Vincerx Pharma?

The following Wall Street analysts have issued research reports on Vincerx Pharma in the last year: Cantor Fitzgerald, and Leerink Partners.
View the latest analyst ratings for VINC.

What is the current price target for Vincerx Pharma?

0 Wall Street analysts have set twelve-month price targets for Vincerx Pharma in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 852.4%. Leerink Partners has the highest price target set, predicting VINC will reach $2.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $2.00 for Vincerx Pharma in the next year.
View the latest price targets for VINC.

What is the current consensus analyst rating for Vincerx Pharma?

Vincerx Pharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VINC will outperform the market and that investors should add to their positions of Vincerx Pharma.
View the latest ratings for VINC.

What other companies compete with Vincerx Pharma?

Other companies that are similar to Vincerx Pharma include Equillium, Akari Therapeutics, Senti Biosciences, Chemomab Therapeutics and Calidi Biotherapeutics. Learn More about companies similar to Vincerx Pharma.

How do I contact Vincerx Pharma's investor relations team?

Vincerx Pharma's physical mailing address is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. The company's listed phone number is 650-800-6676. The official website for Vincerx Pharma is vincerapharma.com. Learn More about contacing Vincerx Pharma investor relations.